A postbiotic product with antiviral, anti-oxidant, anti-inflammatory and mucosal repairing effects, and preparation method and application thereof
Through the liquid and solid fermentation process of Bifidobacterium adolescentis Nice-qcsq, an epibiotic product was developed, which solved the problems of unstable effects and poor anti-inflammatory effects of existing immunity products, and achieved effective against viral infection. Resistance and mucosal repair.
Patent Information
- Application Number
- CN202410493005.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2024-04-23
- Publication Date
- 2024-11-22
- Estimated Expiration
- 2044-04-23
AI Technical Summary
The existing immune products have unstable effects, poor anti-inflammatory effects and cannot repair damaged tissue mucosa, resulting in excessive inflammatory response during viral infection, resulting in tissue damage, and lack of effective immune regulation methods.
Develop an epibiotic product based on Bifidobacterium adolescentis Nice-qcsq. Through a combination of liquid and solid fermentation, its inactivated strains and fermentation metabolites are obtained for the preparation of antiviral, antioxidant, and anti-inflammatory and products that repair mucosa.
This product significantly improves the antiviral and anti-inflammatory effects, reduces tissue damage caused by viral infection, promotes mucosa repair, significantly reduces the level of inflammatory cytokines, and improves the abundance of biologically active substances and practical application value.
Smart Images

Figure CN118620765B_ABST
Abstract
Description
Technical Field
[0001] The present invention belongs to the technical field of microbial preparations, and specifically relates to a postbiotic product with antiviral, antioxidant, anti-inflammatory and mucosal repairing effects, and a preparation method and application thereof. Background Art
[0002] The information disclosed in this background technology section is only intended to enhance the understanding of the overall background of the invention, and should not necessarily be regarded as an admission or any form of suggestion that the information constitutes the prior art already known to a person skilled in the art.
[0003] The immune system is the body's own defense mechanism. It is the body's ability to identify and eliminate any foreign bodies (viruses, bacteria, etc.) that invade from outside, to deal with aging, damaged, dead, and degenerated cells, and to identify and deal with mutant cells and virus-infected cells in the body. The strength of the immune system is directly related to an individual's ability to fight against viral invasion. Improving the body's immunity plays a very important role in preventing and controlling diseases and inhibiting the formation of tumors.
[0004] As an important interface between the body and the external environment, the mucosa not only bears the defensive function of blocking the invasion of pathogens, but is also the main entrance for viral infection. When the virus successfully crosses the mucosal barrier and enters the host, it can quickly invade the host cells and replicate using the host cell mechanism. This process triggers the alarm of the host immune system and triggers an inflammatory response. Inflammation is a natural response of the immune system aimed at clearing the source of infection and repairing damaged tissue. However, in the case of viral infection, the inflammatory response may become excessive, leading to tissue damage and other adverse effects. Therefore, while fully maintaining immune function, reducing the disease burden caused by inflammation, finding ways to regulate the inflammatory response, and preventing excessive tissue damage are expected to provide more effective and precise methods for treating viral infections.
[0005] Although there are some immunity products on the market, they often have some shortcomings, such as unstable effects, poor anti-inflammatory effects, and inability to repair damaged tissue mucosa, etc. These problems make it urgent to find more effective and safe immune regulation methods. Summary of the invention
[0006] Based on the above-mentioned deficiencies in the prior art, the present invention provides a postbiotic product with antiviral, anti-oxidant, anti-inflammatory and mucosal repairing effects, and a preparation method and application thereof. Experiments have shown that the postbiotic product prepared by the present invention can effectively solve the problems of unstable effects, poor anti-inflammatory effects, and inability to repair damaged tissue mucosa of existing products. Based on the above-mentioned research results, the present invention is completed.
[0007] In order to achieve the above technical objectives, the present invention relates to the following technical solutions:
[0008] One aspect of the present invention provides a strain of Bifidobacterium adolescentis Nice-qcsq, which is deposited in the China Center for Type Culture Collection (address: Wuhan University, Luojia Mountain, Wuchang, Wuhan City, Hubei Province), with a preservation date of April 9, 2024, and its biological preservation number is CCTCC NO: M 2024646.
[0009] The second aspect of the present invention provides a postbiotic product comprising at least inactivated Bifidobacterium adolescentis Nice-qcsq and its fermentation metabolites.
[0010] The third aspect of the present invention provides a method for preparing the above-mentioned postbiotic product, and the preparation method specifically comprises:
[0011] S1. Activation of strains: streaking the Bifidobacterium adolescentis Nice-qcsq into activation medium to obtain a pure strain;
[0012] S2. Preparation of primary seed solution: Pick a single colony of Bifidobacterium adolescentis obtained in step S1 and place it in the first culture solution for static culture at 35-37° C. for 14-16 hours to obtain a primary seed solution;
[0013] S3, preparation of secondary seed solution: inoculate the primary seed solution cultured above into the second culture solution under sterile conditions, with an inoculation amount of 3-5%, and culture with stirring at 50-120 rpm, at a temperature of 35-37°C, pH 6.0, and a tank pressure of 0.03-0.06Mpa, and culture for 12-14 hours to obtain the secondary seed solution;
[0014] S4, liquid fermentation of Bifidobacterium adolescentis: inoculate the secondary seed liquid into the third culture liquid at an inoculation rate of 3-5%, 35-37°C, 80-120r / min, air pressure of 0.05MPa, pH 6.5, and culture for 15-18 hours; centrifuge to obtain liquid fermentation sludge;
[0015] S5. Solid fermentation of Bifidobacterium adolescentis: inoculate the liquid fermentation sludge into the solid fermentation medium at an amount of 0.05-0.2%, 28-32° C., stirring speed 10-30 r / min, nitrogen pressure maintained at 0.05 MPa, natural pH, and ferment for 12-14 hours.
[0016] The fourth aspect of the present invention provides the use of the above-mentioned postbiotic products in the preparation of antiviral, antioxidant, anti-inflammatory and mucosal repair products.
[0017] Beneficial technical effects of one or more of the above technical solutions:
[0018] The above technical solution screened a strain of Bifidobacterium adolescentis, and based on this strain, a postbiotic production process based on liquid-solid fermentation was successfully developed. Among them, liquid fermentation usually helps the rapid growth of microorganisms, and solid-state fermentation can provide a more suitable growth environment for strains. By simulating the fermentation environment and metabolic process of healthy human intestinal flora, Bifidobacterium adolescentis and its metabolite active substances are efficiently obtained, and the abundance of bioactive substances is higher, and the antiviral, anti-inflammatory and repair effects are more obvious, so it has good practical application value. BRIEF DESCRIPTION OF THE DRAWINGS
[0019] The accompanying drawings in the specification, which constitute a part of the present invention, are used to provide a further understanding of the present invention. The exemplary embodiments of the present invention and their descriptions are used to explain the present invention and do not constitute improper limitations on the present invention.
[0020] Figure 1 is the behavioral score of each group of rats in the effect verification of the present invention;
[0021] Figure 2 HE slices of lung tissues of each group in the validation of the effect of the present invention;
[0022] Figure 3 HE sections of oral mucosal tissues of rats in each group in the validation of the effect of the present invention;
[0023] Figure 4 This is a graph showing the changes in ulcer area in the model group and the postbiotic group of rats during the period of taking postbiotics in the validation of the effect of the present invention. DETAILED DESCRIPTION
[0024] It should be noted that the following detailed descriptions are exemplary and are intended to provide further explanation of the present invention. Unless otherwise specified, all technical and scientific terms used in the present invention have the same meanings as those commonly understood by those skilled in the art to which the present invention belongs.
[0025] It should be noted that the terms used herein are only for describing specific embodiments and are not intended to limit the exemplary embodiments of the present invention. As used herein, unless the context clearly indicates otherwise, the singular form is also intended to include the plural form. In addition, it should be understood that when the terms "comprising" and / or "including" are used in this specification, it indicates the presence of features, steps, operations, devices, components and / or combinations thereof.
[0026] In a typical embodiment of the present invention, a strain of Bifidobacterium adolescentis Nice-qcsq is provided, which is deposited in the China Type Culture Collection (address: Wuhan University, Luojia Mountain, Wuchang, Wuhan City, Hubei Province), the preservation date is April 9, 2024, and its biological preservation number is CCTCC NO: M 2024646.
[0027] In another specific embodiment of the present invention, a postbiotic product is provided, which at least comprises inactivated Bifidobacterium adolescentis Nice-qcsq and its fermentation metabolites.
[0028] In another specific embodiment of the present invention, a method for preparing the above-mentioned postbiotic product is provided, and the preparation method specifically comprises:
[0029] S1. Activation of strains: streaking the Bifidobacterium adolescentis Nice-qcsq into activation medium to obtain a pure strain;
[0030] The composition of the activation culture medium is as follows: per 1000 mL, 10-15 g protein Chen, 5-10 g beef powder, 2-5 g yeast powder, 1-2 g glucose, 0.5-1.0 mL Tween 80, 1-2 g dipotassium hydrogen phosphate, 3-5 g sodium acetate, 1-2 g triammonium citrate, 0.1-0.2 g magnesium sulfate, 0.05-0.1 g manganese sulfate, 10-15 g fucoidan, 15-20 g agar powder, and the pH is adjusted to 7.0;
[0031] More specifically, the composition of the activation culture medium is as follows: per 1000 mL, it contains 10 g peptone, 5 g beef powder, 5 g yeast powder, 2 g glucose, 1.0 mL Tween 80, 2 g dipotassium hydrogen phosphate, 5 g sodium acetate, 2 g triammonium citrate, 0.1 g magnesium sulfate, 0.05 g manganese sulfate, 10 g fucoidan, 20 g agar powder, and the pH is adjusted to 7.0.
[0032] S2. Preparation of primary seed solution: Pick a single colony of Bifidobacterium adolescentis obtained in step S1 and place it in the first culture solution for static culture at 35-37° C. for 14-16 hours to obtain a primary seed solution;
[0033] The composition of the first culture solution is as follows: 10-15g casein, 5-10g beef powder, 2-5g yeast powder, 1-2g glucose, 1-2g soybean peptide, 1-2g wheat peptide, 2-5g oligofructose, 10-15g fucoidan per 1000mL, and the pH is adjusted to 7.0;
[0034] More specifically, the composition of the first culture solution is as follows: 15g casein, 10g beef powder, 5g yeast powder, 2g glucose, 2g soybean peptide, 2g wheat peptide, 5g oligofructose, 15g fucoidan per 1000mL, and the pH is adjusted to 7.0.
[0035] S3, preparation of secondary seed solution: inoculate the primary seed solution cultured above into the second culture solution under sterile conditions, with an inoculation amount of 3-5%, and culture with stirring at 50-120 rpm, at a temperature of 35-37°C, pH 6.0, and a tank pressure of 0.03-0.06Mpa, and culture for 12-14 hours to obtain the secondary seed solution;
[0036] The composition of the second culture solution is as follows: 10-15g casein, 5-10g peptone, 2-5g yeast powder, 1-2g glucose, 1-2g soybean peptide, 1-2g wheat peptide, 5-10g oligofructose, 15-20g fucoidan per 1000mL, pH natural;
[0037] More specifically, the composition of the second culture solution is as follows: 15g casein, 10g peptone, 5g yeast powder, 2g glucose, 1g soybean peptide, 1g wheat peptide, 10g oligofructose, 20g fucoidan per 1000mL, pH natural.
[0038] S4, liquid fermentation of Bifidobacterium adolescentis: inoculate the above-mentioned secondary seed liquid into the third culture liquid, with an inoculation amount of 3-5%, 35-37°C, 80-120r / min, air pressure of 0.05MPa, pH 6.5, and culture for 15-18 hours;
[0039] Further, liquid fermentation sludge is obtained by centrifugation; the water content of the fermentation sludge is controlled to be 60-80%, preferably 70%.
[0040] The composition of the third culture solution is as follows: 15-20g casein, 15-20g peptone, 10-15g yeast powder, 1-2g glucose, 10-15g water-soluble starch, 1-2g wheat peptide, 2-5g glycine, 2-5g tyrosine, 5-10g oligofructose, 15-20g fucoidan, 0.05-0.2% polyether defoamer, pH 6.5 per 1000mL;
[0041] Specifically, the composition of the third culture solution is as follows: per 1000 mL, it contains 20g casein, 20g peptone, 15g yeast powder, 2g glucose, 10g water-soluble starch, 2g wheat peptide, 5g glycine, 5g tyrosine, 10g oligofructose, 20g fucoidan, 0.05-0.2% polyether defoamer, pH 6.5.
[0042] S5. Solid fermentation of Bifidobacterium adolescentis: inoculate 0.05-0.2% of the solid fermentation medium, ferment for 12-14 hours at 28-32°C, stirring speed 10-30 r / min, nitrogen pressure maintained at 0.05 MPa, pH natural.
[0043] The solid fermentation medium is composed of: 100-200 parts of soybean peptide, 50-100 parts of wheat peptide, 50-100 parts of casein, 100-200 parts of isomaltooligosaccharide, 100-200 parts of fructooligosaccharide, 50-100 parts of proline, 50-100 parts of skim milk powder, 50-100 parts of glycine, 50-100 parts of tyrosine, 100-200 parts of fucoidan, and natural pH.
[0044] The composition of the solid fermentation medium is as follows: 100g soybean peptide, 100g wheat peptide, 100g casein, 100g isomaltooligosaccharide, 150g fructooligosaccharide, 50g proline, 100g skim milk powder, 50g glycine, 50g tyrosine, 200g fucoidan per 1000g, and the pH is natural.
[0045] Furthermore, the product obtained in step S5 is sterilized at high temperature, cooled to room temperature (such as 30° C.), and freeze-dried to obtain the postbiotic product.
[0046] Specifically, the specific conditions for high temperature sterilization are: raising the temperature to 90° C. and maintaining for 40 minutes.
[0047] In another specific embodiment of the present invention, there is provided the use of the above-mentioned postbiotic product in the preparation of antiviral, antioxidant, anti-inflammatory and mucosal repair products.
[0048] The anti-oxidation, anti-inflammatory and mucosal repair products are medicines.
[0049] Specifically, in the influenza virus infection pneumonia mouse model established by intranasal drops of influenza virus, after the administration of the above-mentioned postbiotic products, the symptoms of rats such as scratching their noses, sneezing, and runny nose were significantly alleviated, and the oxidative stress indicators of rat lung injury were effectively intervened. At the same time, the content of TNF-α, IL-6 and IL-1β in rat lung tissue was effectively reduced, and the inflammatory cell infiltration and alveolar wall thickening of rat lung tissue taking postbiotics were significantly reduced, and the alveolar structure was clearer. This shows that it has a certain repair effect on viral lung injury; further oral ulcer models can also prove that postbiotics have anti-inflammatory effects and can promote mucosal repair by promoting epidermal growth factor (EGF).
[0050] The medicine may comprise a carrier, an excipient and a diluent, and its dosage form is an oral preparation in the form of powder, granules, tablets, capsules, suspensions, emulsions, syrups, sprays, or an injection in the form of a sterile injection solution.
[0051] The product can be a medicine, and the medicine can also include an appropriate amount of carriers, excipients and diluents commonly used. Moreover, according to the usual method, it can be made into a dosage form of oral agents such as powders, granules, tablets, capsules, suspensions, emulsions, syrups, sprays, and sterile injection solutions. The non-pharmaceutical active ingredients such as carriers, excipients and diluents that can be included in the present invention are well known in the field, and those of ordinary skill in the art can determine that they meet clinical standards. The carriers, excipients and diluents of the present invention include but are not limited to lactose, glucose, sorbitol, mannitol, xylitol, maltitol, starch, gum arabic, gelatin, calcium phosphate, cellulose, microcrystalline cellulose, polyvinyl pyrrolidone, water and mineral oil, etc. It is not specifically limited here.
[0052] The present invention is further explained by the following examples, but they are not intended to limit the present invention. It should be understood that these examples are only used to illustrate the present invention and are not intended to limit the scope of the present invention. In each example,
[0053] The composition of the activation culture medium is as follows: per 1000 mL, it contains 10 g peptone, 5 g beef powder, 5 g yeast powder, 2 g glucose, 1.0 mL Tween 80, 2 g dipotassium hydrogen phosphate, 5 g sodium acetate, 2 g triammonium citrate, 0.1 g magnesium sulfate, 0.05 g manganese sulfate, 10 g fucoidan, 20 g agar powder, and the pH is adjusted to 7.0.
[0054] The composition of the first culture medium is as follows: 15g casein, 10g beef powder, 5g yeast powder, 2g glucose, 2g soybean peptide, 2g wheat peptide, 5g oligofructose, 15g fucoidan per 1000mL, and the pH is adjusted to 7.0;
[0055] The composition of the second culture medium is as follows: 15 g casein, 10 g peptone, 5 g yeast powder, 2 g glucose, 1 g soybean peptide, 1 g wheat peptide, 10 g oligofructose, 20 g fucoidan per 1000 mL, pH natural.
[0056] The composition of the third culture medium is as follows: per 1000 mL, it contains 20g casein, 20g peptone, 15g yeast powder, 2g glucose, 10g water-soluble starch, 2g wheat peptide, 5g glycine, 5g tyrosine, 10g oligofructose, 20g fucoidan, 0.05-0.2% polyether defoamer, and 20% NaOH to adjust pH to 6.5.
[0057] The composition of the solid fermentation medium is as follows: 100 g soybean peptide, 100 g wheat peptide, 100 g casein, 100 g isomaltooligosaccharide, 150 g fructooligosaccharide, 50 g proline, 100 g skim milk powder, 50 g glycine, 50 g tyrosine, 200 g fucoidan per 1000 g, pH natural.
[0058] Example 1
[0059] A method for preparing postbiotics comprises the following steps:
[0060] Streaking the Bifidobacterium adolescentisNice-qcsq into an activation medium to obtain a pure strain;
[0061] Pick a single colony of Bifidobacterium adolescentisNice-qcsq obtained in the above step, place it in the first culture solution and culture it at 35°C for 14 hours to obtain a primary seed solution;
[0062] The first-level seed solution cultured above was inoculated into the seed tank containing the second culture solution under sterile conditions, with an inoculation amount of 3%, stirring culture at 100 rpm, temperature of 37°C, pH 6.0, tank pressure of 0.05 MPa, and cultured for 12-14 hours to obtain the second-level seed solution;
[0063] The secondary seed liquid is inoculated into a fermenter containing the sterilized third culture liquid, the inoculation amount is 3%, 37°C, 100r / min, the air pressure is maintained at 0.05MPa, 20% NaOH is used to adjust the pH to 6.5, and the culture is carried out for 15-18 hours;
[0064] The liquid fermentation sludge with a water content of 70% was obtained by centrifugation in a tubular centrifuge;
[0065] The liquid fermentation sludge was inoculated into the solid fermentation medium at 0.1%, and the temperature was 30°C, the stirring speed was 20 r / min, the nitrogen pressure was maintained at 0.05 MPa, the pH was natural, and the fermentation was carried out for 14 hours; after 14 hours, the fermentation tank was heated to 90°C, maintained for 40 minutes, and then cooled to 30°C, and the sample was obtained after freeze-drying.
[0066] Example 2
[0067] A method for preparing postbiotics comprises the following steps:
[0068] Streaking the Bifidobacterium adolescentisNice-qcsq into an activation medium to obtain a pure strain;
[0069] Pick a single colony of Bifidobacterium adolescentisNice-qcsq obtained in the above step, place it in the first culture solution and culture it at 35°C for 14 hours to obtain a primary seed solution;
[0070] The first-level seed solution cultured above was inoculated into the seed tank containing the second culture solution under sterile conditions, with an inoculation amount of 3%, stirring culture at 100 rpm, temperature of 37°C, pH 6.0, tank pressure of 0.05 MPa, and cultured for 12-14 hours to obtain the second-level seed solution;
[0071] The secondary seed liquid is inoculated into a fermenter containing the sterilized third culture liquid, the inoculation amount is 3%, 37°C, 100r / min, the air pressure is maintained at 0.05MPa, 20% NaOH is used to adjust the pH to 6.5, and the culture is carried out for 15-18 hours;
[0072] The liquid fermented bacterial sludge with a water content of 70% was obtained by centrifugation in a tubular centrifuge; 20% skim milk powder was added and freeze-dried to obtain a sample.
[0073] Effect verification
[0074] The antioxidant and anti-inflammatory postbiotics are verified by:
[0075] 40 healthy Wistar male rats with uniform weight were selected, and 10 rats were taken as the control group. Except for the control group, the rats in the other groups were injected with OVA (ovalbumin) and dripped to establish a nasal mucosal sensitivity model, and then the influenza virus infection pneumonia model was established by nasal drops of influenza virus. 30 mucosal sensitive and pneumonia rat models were randomly divided into 10 groups, each group of 10 rats, respectively, model group, Example 1 group and Example 2 group. Rats in the normal group and model group were gavaged with normal saline, and rats in each postbiotic group were gavaged with 0.05g / kg / d of postbiotics for 4 consecutive weeks. After 4 weeks, behavioral symptoms were scored according to the number of sneezes and the degree of runny nose. Sneezing 1-3 times was 1 point, 4-9 times was 2 points, and 9 or more times was 3 points; scratching the nose 0-5 times was 1 point, 6-9 times was 2 points, and 9 or more times was 3 points; snot did not flow out, snot flowed out of the nostrils, and tears were 1, 2, and 3 points respectively.
[0076] 24 hours after the last intragastric administration, the rats were anesthetized with sodium pentobarbital, and the nasal mucosa and lung tissues of the rats were taken, and the pathological conditions of the tissues of the rats were observed by HE staining. The levels of inflammatory cytokines TNF-α, IL-6 and IL-1β in the tissues were detected by ELISA. The levels of malondialdehyde (MDA) and superoxide dismutase (SOD) in the serum were also analyzed and determined.
[0077] Rats in the normal group occasionally scratched their noses and sneezed, but had no runny nose and normal appetite. Rats in the model group scratched their noses and sneezed frequently, or scratched their ears, and had clear runny nose that exceeded the nostrils and poor appetite. Compared with the model group, the behavioral scores of the postbiotic groups decreased, and the solid-liquid fermentation postbiotic group (i.e., Example 1) decreased significantly, and the symptoms of scratching the nose, sneezing, and runny nose in rats were alleviated.
[0078] Compared with the control group, the MDA value in the serum of the rats in the model group increased and the SOD activity decreased. After taking the solid-liquid fermentation postbiotics (i.e., Example 1), the MDA value decreased and the SOD activity level increased. This shows that the solid-liquid fermentation postbiotics (i.e., Example 1) can resist oxidation and effectively intervene in the oxidative stress indicators of rat lung injury.
[0079] Table 1. Malondialdehyde and superoxide dismutase levels in rats of each group
[0080]
[0081] Compared with the control group, the TNF-α, IL-6 and IL-1β contents in the lung homogenate of the rats in the model group were significantly increased. After treatment with solid-liquid fermentation postbiotics (i.e., Example 1), the TNF-α, IL-6 and IL-1β contents were significantly reduced. This shows that the intervention of solid-liquid fermentation postbiotics (i.e., Example 1) can effectively reduce the contents of TNF-α, IL-6 and IL-1β in rat lung tissue.
[0082] Table 2. IL-1β, IL-6 and TNF-α levels in rats in each group
[0083]
[0084] The pathological morphology of lung tissues of rats in each group was as follows Figure 2 As shown. The alveolar structure of the rats in the control group was intact and the alveolar septa were normal, while the alveolar structure of the rats in the pneumonia model group was severely damaged, with a large amount of necrotic tissue fragments. After taking the postbiotics in Example 1, the inflammatory cell infiltration and alveolar wall thickening of the rat lung tissue were significantly reduced, and the alveolar structure was clearer (see Figure 2 This shows that postbiotics have a certain repair effect on viral lung damage.
[0085] The postbiotics for mucosal repair are verified by the following method: 40 healthy Wistar male rats with uniform weight are selected, 10 rats are taken as the control group, and the rest of the rats are used to establish an oral ulcer model by chemical burning method except the control group, and the pseudomembrane diameter of the ulcer surface is about 1-2 mm and the color is grayish yellow, indicating that the oral ulcer rat model is successfully prepared. 30 model rats were randomly divided into 10 groups, each group of 10 rats, respectively, the model group, the embodiment 1 group and the embodiment 2 group. The normal group and the model group rats were gavaged with normal saline, and the rats in each postbiotic group were gavaged with 0.05g / kg / d of postbiotics, and fed continuously for 4 weeks. The changes in the area of oral ulcers in each group of rats were measured every weekend. After 4 weeks, the oral mucosa of the rats was taken separately, and the pathological conditions of the rat mucosal tissue were observed by HE staining, and the levels of inflammatory cytokines TNF-α, IL-6 and IL-1β and epidermal growth factor (EGF) in the tissue were detected by ELISA.
[0086] As can be seen from Table 3, compared with the control group, the levels of TNF-α, IL-6 and IL-1β in the model group were increased, and the level of EGF was decreased. Compared with the model group, the levels of TNF-α, IL-6 and IL-1β in the postbiotic example 1 group were gradually decreased, and the level of EGF was gradually increased. It can be seen that the postbiotic group has anti-inflammatory effects and can promote the repair of mucosa by promoting epidermal growth factor (EGF).
[0087] Table 3. TNF-α, IL-6, IL-1β and EGF levels in rats in each group
[0088]
[0089] Depend on Figure 3 and Figure 4 It can be seen that compared with the control group, the rats in the model group had a large amount of inflammatory cell infiltration and a larger ulcer area, while the inflammatory infiltration of the rats in the postbiotic group (ie, Example 1) gradually decreased and the ulcer area gradually healed.
[0090] Finally, it should be noted that the above is only a preferred embodiment of the present invention and is not intended to limit the present invention. Although the present invention has been described in detail with reference to the aforementioned embodiments, it is still possible for those skilled in the art to modify the technical solutions described in the aforementioned embodiments, or to perform equivalent replacements on parts thereof. Any modifications, equivalent replacements, improvements, etc. made within the spirit and principles of the present invention should be included in the protection scope of the present invention. Although the above describes the specific implementation methods of the present invention, it is not intended to limit the protection scope of the present invention. Those skilled in the art should understand that, based on the technical solution of the present invention, various modifications or deformations that can be made by those skilled in the art without creative labor are still within the protection scope of the present invention.
Claims
1. A postbiotic product, characterized in that: It contains at least inactivated Bifidobacterium adolescentis ( Bifidobacterium adolescentis )Nice-qcsq and its fermentation metabolites; The Bifidobacterium adolescentis ( Bifidobacterium adolescentis )Nice-qcsq, deposited in China Center for Type Culture Collection on April 9, 2024, and its biological deposit number is CCTCC NO: M 2024646; The preparation method of the postbiotic product specifically comprises: S1. Activation of bacterial strains: The Bifidobacterium adolescentis Bifidobacterium adolescentis Nice-qcsq was streaked into activation medium to obtain pure strains; S2. Preparation of primary seed solution: Pick a single colony of Bifidobacterium adolescentis obtained in step S1 and place it in the first culture solution for static culture at 35-37°C for 14-16 hours to obtain a primary seed solution; S3, preparation of secondary seed solution: inoculate the primary seed solution cultured above into a seed tank containing the second culture solution under sterile conditions, with an inoculation amount of 3-5%, stirring culture at 50-120 rpm, temperature 35-37 ° C, pH 6.0, tank pressure 0.03-0.06 Mpa, and culture for 12-14 hours to obtain the secondary seed solution; S4, liquid fermentation of Bifidobacterium adolescentis: inoculate the secondary seed liquid into a fermentation tank containing the third culture liquid, with an inoculation amount of 3-5%, 35-37°C, 80-120 r / min, air pressure of 0.05 MPa, pH 6.5, and culture for 15-18 hours; centrifuge to obtain liquid fermentation sludge, wherein the water content of the liquid fermentation sludge is 70%; S5. Solid fermentation of Bifidobacterium adolescentis: inoculate the liquid fermentation sludge into the solid fermentation medium at an amount of 0.05-0.2%, 28-32 ℃, stirring speed 10-30 r / min, nitrogen pressure maintained at 0.05 MPa, pH natural, ferment for 12-14 hours, heat the fermentation tank to 90 ℃, maintain for 40 min, then cool to 30 ℃, and freeze-dry to obtain the sample.
2. The postbiotic product according to claim 1, characterized in that In step S1, the composition of the activation culture medium is as follows: 10-15 g protein Chen, 5-10 g beef powder, 2-5 g yeast powder, 1-2 g glucose, 0.5-1.0 mL Tween 80, 1-2 g dipotassium hydrogen phosphate, 3-5 g sodium acetate, 1-2 g triammonium citrate, 0.1-0.2 g magnesium sulfate, 0.05-0.1 g manganese sulfate, 10-15 g fucoidan, 15-20 g agar powder per 1000 mL, and the pH is adjusted to 7.
0.
3. The postbiotic product according to claim 1, characterized in that In step S2, the composition of the first culture solution is as follows: 10-15 g casein, 5-10 g beef powder, 2-5 g yeast powder, 1-2 g glucose, 1-2 g soybean peptide, 1-2 g wheat peptide, 2-5 g oligofructose, 10-15 g fucoidan per 1000 mL, and the pH is adjusted to 7.
0.
4. The postbiotic product according to claim 1, characterized in that In step S3, the composition of the second culture solution is as follows: 10-15 g casein, 5-10 g peptone, 2-5 g yeast powder, 1-2 g glucose, 1-2 g soybean peptide, 1-2 g wheat peptide, 5-10 g oligofructose, 15-20 g fucoidan per 1000 mL, and the pH is natural.
5. The postbiotic product according to claim 1, characterized in that In step S4, the composition of the third culture solution is as follows: 15-20 g casein, 15-20 g peptone, 10-15 g yeast powder, 1-2 g glucose, 10-15 g water-soluble starch, 1-2 g wheat peptide, 2-5 g glycine, 2-5 g tyrosine, 5-10 g oligofructose, 15-20 g fucoidan, 0.05-0.2% polyether defoamer, pH 6.5 per 1000 mL.
6. The postbiotic product according to claim 1, characterized in that In step S5, the composition of the solid fermentation medium is as follows: 100-200 parts of soybean peptide, 50-100 parts of wheat peptide, 50-100 parts of casein, 100-200 parts of isomaltooligosaccharide, 100-200 parts of fructooligosaccharide, 50-100 parts of proline, 50-100 parts of skim milk powder, 50-100 parts of glycine, 50-100 parts of tyrosine, 100-200 parts of fucoidan, and the pH is natural.
7. Use of the postbiotic product according to claim 1 in the preparation of drugs for repairing viral lung damage, anti-inflammatory lung tissue, and repairing oral mucosa.
